{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:43:11Z","timestamp":1793763791500,"version":"4.6.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The success of chimeric antigen receptor (CAR) T-cell therapy in adult patients with hematologic malignancies has resulted in a large number of long-term survivors who may experience late complications distinct from those in the early CAR T-cell treatment period. These late complications, defined as occurring more than 90 days after CAR T-cell infusion, include cytopenias, infections, secondary malignancies, and delayed neurotoxicities. Late cytopenias may be from prolonged recovery after lymphodepleting (LD) chemotherapy or arise anew, raising concerns for recurrent primary disease or a secondary malignancy. Cytopenias are treated with supportive care, hematopoietic cytokines, and, occasionally, hematopoietic stem cell support. LD chemotherapy profoundly affects B, T, and natural killer cells. CD19 and B-cell maturation antigen are expressed on normal B cells and plasma cells, respectively, and the targeting of these structures by CAR T-cell products can result in prolonged lymphopenias and hypogammaglobulinemia, making infection an ongoing risk. Late infections are predominantly due to respiratory viruses, reactivation of herpes viruses, and Pneumocystis jirovecii. Patients may require ongoing prophylaxis and immunoglobulin replacement therapy. Although responses may be blunted, vaccinations are generally recommended for most adult CAR T-cell patients. Both hematologic and solid secondary malignancies are a known risk of CAR T-cell therapy; retroviruses used to produce CAR T-cell products have resulted in T-cell cancers secondary to insertional oncogenesis. It is essential to monitor for late complications in adult patients receiving CAR T-cells by using a multidisciplinary approach between referring hematologist oncologists and cell therapy centers to improve the outcomes and quality of life for these patients.<\/jats:p>","DOI":"10.1182\/hematology.2024000534","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:02:12Z","timestamp":1733497332000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Late complications and long-term care of adult CAR T-cell patients"],"prefix":"10.1182","volume":"2024","author":[{"given":"Michael R.","family":"Bishop","sequence":"first","affiliation":[{"name":"The David and Etta Jonas Center for Cellular Therapy, Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"7949","key":"2024121115351280700_hem2024000534C1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"2024121115351280700_hem2024000534C2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"2024121115351280700_hem2024000534C3","first-page":"2452","article-title":"How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy","volume":"141","author":"Gutierrez","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2024121115351280700_hem2024000534C4","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024121115351280700_hem2024000534C5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"7897","key":"2024121115351280700_hem2024000534C6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"16","key":"2024121115351280700_hem2024000534C7","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/bloodadvances.2021006193","article-title":"Long-term safety for patients with tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma","volume":"6","author":"Jaeger","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024121115351280700_hem2024000534C8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabta-gene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121115351280700_hem2024000534C9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/hematology.2023000422","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"2023","author":"Epperly","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2024121115351280700_hem2024000534C10","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024121115351280700_hem2024000534C11","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"2024121115351280700_hem2024000534C12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"2024121115351280700_hem2024000534C13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11910-023-01315-w","article-title":"Neurotoxicity of cancer immunotherapies including CAR T cell therapy","volume":"23","author":"Song","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3-4","key":"2024121115351280700_hem2024000534C14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminoncol.2024.02.001","article-title":"CAR T-cell therapy: a collaboration between authorized treatment centers and community oncologists","volume":"51","author":"Bishop","year":"2024","journal-title":"Semin Oncol"},{"issue":"5","key":"2024121115351280700_hem2024000534C15","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"2024121115351280700_hem2024000534C16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115351280700_hem2024000534C17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2024121115351280700_hem2024000534C18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024121115351280700_hem2024000534C19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024121115351280700_hem2024000534C20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19- targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2024121115351280700_hem2024000534C21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2024121115351280700_hem2024000534C22","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024121115351280700_hem2024000534C23","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"issue":"12S","key":"2024121115351280700_hem2024000534C24","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","article-title":"[Prevention and management of infections in patients undergoing CAR T-cell therapy: recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"108","author":"Paul","year":"2021","journal-title":"Bull Cancer"},{"issue":"2","key":"2024121115351280700_hem2024000534C25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"4","key":"2024121115351280700_hem2024000534C26","doi-asserted-by":"crossref","first-page":"277.e1","DOI":"10.1016\/j.jtct.2022.08.011","article-title":"Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-cell therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024121115351280700_hem2024000534C27","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"2024121115351280700_hem2024000534C28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.2022016175","article-title":"Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell- depleted lymphoma after CART therapy","volume":"140","author":"Atanackovic","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024121115351280700_hem2024000534C29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","article-title":"Frequently asked questions on coronavirus disease 2019 vaccination for hematopoietic cell transplantation and chimeric antigen receptor T-cell recipients from the American Society for Transplantation and Cellular Therapy and the American Society of Hematology","volume":"29","author":"Khawaja","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024121115351280700_hem2024000534C30","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2024121115351280700_hem2024000534C31","unstructured":"Topp\n              M\n            , FeuchtingerT.\n          Management of hypogammaglobulinaemia and B-cell aplasia. In: Kr\u00f6gerN, GribbenJ, ChabannonC, Yakoub-AghaI, EinseleH, eds. The EBMT\/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 28. Access date: 7February2022, https:\/\/www.ebmt.org\/sites\/default\/files\/2022-02\/2022_Book_TheEBMTEHACAR-TCellHandbook.pdf."},{"issue":"2","key":"2024121115351280700_hem2024000534C32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"2024121115351280700_hem2024000534C33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2024121115351280700_hem2024000534C34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2024121115351280700_hem2024000534C35","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024121115351280700_hem2024000534C36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41409-020-01029-4","article-title":"Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2024121115351280700_hem2024000534C37","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2021004889","article-title":"Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma","volume":"5","author":"Jung","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2024121115351280700_hem2024000534C38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","article-title":"Long-term neurologic safety in patients with b-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy","volume":"99","author":"Ursu","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"2024121115351280700_hem2024000534C39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024121115351280700_hem2024000534C40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024121115351280700_hem2024000534C41","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"2024121115351280700_hem2024000534C42","first-page":"JCO2302786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","author":"Jain","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/109\/2346372\/109bishop.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/109\/2346372\/109bishop.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T16:48:05Z","timestamp":1733935685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/109\/526152\/Late-complications-and-long-term-care-of-adult-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000534","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}